[Tisserand & Young 2014] Essential Oil Safety: A Guide for Health Care Professionals, 2nd ed., Churchill Livingstone Elsevier (B216, p.817-819). Primary clinical safety source.
[Güllüce, M., Sökmen, M., Daferera, D., et al] antioxidant + antimicrobial activity research source.
[Radonic, A. & Milos, M.] antioxidant activity research source.
[Lampronti, I., et al] K562 myelogenous leukemia IC50 85.4 µg/mL summer / 56.15 µg/mL winter cytotoxicity research-positive.
[Mosaffa, F., et al] summer savory rat lymphocyte H2O2-genotoxicity protection research source.
[Zani, F., et al] non-mutagenic Bacillus subtilis rec-assay + Salmonella/microsome reversion confirmation research source.
[B216 Chapter 14 — Carvacrol profile] class-mechanism source for 1% dermal-irritation cap-driver framework.
[B216 Chapter 14 — Thymol profile] class-mechanism source for 1% dermal-irritation cap-driver framework.
[B216 Chapter 14 — Methyleugenol profile] class-mechanism source for EU/IFRA 0.0002-0.0004% finished-product carcinogen-class cap.
[B216 Chapter 14 — Estragole profile] class-mechanism source for IFRA 0.01% leave-on cap.
[B216 Chapter 14 — β-Caryophyllene +] class-mechanism source for anticarcinogenic activity research-positive counter-rail.
[B216 Table 4.10B + Box 7.1] drug-interaction antidiabetic + anticoagulant cardiovascular class-rail source.
[IFRA 2009] methyleugenol + estragole leave-on cosmetic caps.
[European Commission 2002] SCCNFP methyleugenol 0.0002% finished-product cap.
[APG-IV] Lamiaceae family + Lamiales order taxonomy.